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Secukinumab Provides Sustained Improvements in the 
Signs and Symptoms of Psoriatic Arthritis: Final 5-year 
Results from the Phase 3 FUTURE 1 Study
Philip J. Mease,1  Arthur Kavanaugh,2 Andreas Reimold,3 Hasan Tahir,4 Juergen Rech,5  Stephen Hall,6 
Piet Geusens,7 Pascale Pellet,8 Eumorphia Maria Delicha,8 Luminita Pricop,9 Shephard Mpofu,8 and on behalf of 
the FUTURE 1 study group
Objective. To report the 5-year efficacy and safety of secukinumab in the treatment of patients with psoriatic 
arthritis (PsA) in the FUTURE 1 study (NCT01392326).
Methods. Following the 2-year core trial, eligible patients receiving subcutaneous secukinumab entered a 3-year 
extension phase. Results are presented for key efficacy endpoints for the secukinumab 150-mg group (n = 236), in-
cluding patients who escalated from 150 to 300 mg (approved doses) starting at week 156. Safety is reported for all 
patients (n = 587) who received 1 dose or more of study treatment.
Results. Overall, 81.8%% (193 of 236) of patients in the secukinumab 150-mg group completed 5 years of 
treatment, of which 36.4% (86 of 236) had dose escalation from 150 to 300 mg. Sustained improvements were 
achieved with secukinumab across all key efficacy endpoints through 5 years. Overall, 71.0%/51.8%/36.3% of 
patients achieved American College of Rheumatology (ACR) 20/50/70 responses at 5 years. Efficacy improved 
in patients requiring dose escalation from 150 to 300 mg and was comparable with those who did not require 
dose escalation. Exposure-adjusted incidence rates for selected adverse events per 100 patient-years for any 
secukinumab dose were serious infections (1.8), Crohn’s disease (0.2), Candida infection (0.9), and major adverse 
cardiac events (0.5).
Conclusion. Secukinumab provided sustained improvements in the signs and symptoms in the major clinical do-
mains of PsA. Efficacy improved for patients requiring dose escalation from 150 to 300 mg during the study. Secuki-
numab was well tolerated with no new safety signals.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, inflammatory disease 
characterized by peripheral arthritis, axial disease, dactylitis, 
enthesitis, and skin and nail psoriasis (1,2). PsA can negatively 
affect patients’ daily functioning and quality of life as a result of 
permanent joint damage and disability (3). The reported preva-
lence of PsA in the general population is up to 1%, and it affects 
around 30% of patients with psoriasis (2,4,5).
Biologic therapies, such as anti–tumor necrosis factor (TNF) 
and anti–interleukin (IL)-17A antibodies, are recommended for 
the treatment of PsA in patients who experience an inadequate 
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response to first-line treatment with nonsteroidal anti-inflammatory 
drugs (NSAIDs) and/or disease-modifying antirheumatic drugs 
(DMARDs) (6–8). The proinflammatory cytokine IL-17A medi-
ates multiple biological functions that result in joint and entheseal 
inflammation and structural damage, which are characteristic of 
PsA (9,10). Recommendations from the European League Against 
Rheumatism (EULAR) (8) and the Group for Research and Assess-
ment of Psoriasis and Psoriatic Arthritis (GRAPPA) (11) recognize 
targeting IL-17A as a therapeutic strategy to manage all the main 
clinical manifestations of PsA.
Secukinumab, a human monoclonal antibody that directly 
inhibits IL-17A, provided rapid and significant improvements 
in all key clinical manifestations of PsA in the FUTURE 1 
study (NCT01392326) with improvements sustained through 
3 years (12–14). These clinical benefits have been observed 
in patients naïve to biologic therapy and in those with an 
intolerance or inadequate response to agents targeting TNF 
(3,8,9,11,13–16).
Data from FUTURE 1 have also shown that secukinumab sig-
nificantly inhibits joint structural damage through 24 weeks (14), 
with benefits sustained out to 3 years (3); it is worth noting that 
radiographic data were only collected up to 3 years in this study 
(3,17). Here, we present the final 5-year efficacy and safety results, 
including efficacy results in patients who had a dose escalation 
from 150 to 300 mg during the study.
METHODS
Study population. The study design of FUTURE 1 has 
been described in detail elsewhere (3). In brief, the population of 
the core study consisted of adults diagnosed with PsA, as clas-
sified by Classification Criteria for Psoriatic Arthritis (CASPAR) 
criteria (18), and with moderate to severe symptoms for 6 
months or more, who must have 3 or more tender joints of 78 
and 3 or more swollen joints of 76 at baseline. Patients were 
classed as anti-TNF inadequate responders (anti-TNF-IR) if they 
had been taking an anti-TNF agent at an adequate dose for 3 
months or longer, had experienced an inadequate response, or 
had stopped treatment because of tolerability issues.
Clinical judgement of the investigator was used to assess 
the suitability of a patient to enter the extension study based 
upon overall improvement and response to therapy during the 
core study. Only participants who had completed the 2-year 
core study and had signed the new informed consent form were 
included in the extension phase. Key exclusion criteria for the 
extension included patients who were deemed not to be bene-
fiting from the study treatment based upon lack of improvement 
or worsening of their symptoms, patients receiving therapy with 
biologic immunomodulation agents other than secukinumab, 
and those with inflammatory disorders other than PsA, including 
active ongoing inflammatory bowel disease (IBD), which might 
confound the evaluation of therapy.
Study oversight and design. This study was approved 
by institutional review boards or ethics committees for each study 
center and was conducted in accordance with the Declaration of 
Helsinki. All patients provided written informed consent prior to 
participation and again at the start of the extension study.
This extension study employed a parallel group, double-blind 
design for the first year (up to and excluding week 156 [the 2-year 
core study plus the first year of the extension study]), followed by 
an open-label design for the next two years (week 156 onward). 
Blinding during the first year of the extension study was required 
to ensure that all patients had completed the core study and the 
data was locked before unblinding occurred. Investigators used 
their clinical judgment to decide if it was beneficial for patients to 
enter the extension study based upon overall improvement and 
response to therapy during the 2-year period of the core study.
At 2 years in the core study, eligible patients completed assess-
ments and continued on the same dose as that received during the 
core study (secukinumab at a dosage of 150 mg or 75 mg every 
4 weeks). Study treatment dose adjustments were not permitted 
until week 156. During the open label study period starting at week 
156, the secukinumab dose could be escalated from 75 to 150 or 
300 mg or from 150 to 300 mg for patients whose signs and symp-
toms were not fully controlled with the current dose as judged by the 
investigator. Here, we report long-term results for the secukinumab 
150-mg group, including patients who switched from placebo to 
secukinumab 150 mg at weeks 16 or 24 following the end of the pla-
cebo-controlled period. We also report efficacy results for patients 
who escalated from secukinumab 150 to 300 mg (approved doses).
For all patients who discontinued or withdrew from the study, 
the investigator was to ensure that the patient completed an end-
of-treatment visit (corresponding to the last visit for the patient’s 
current period of treatment) 4 weeks after last study treatment, 
and also returned after an additional 8 weeks for a final follow-up 
visit (12 weeks after last study treatment).
Endpoints and assessments. The primary endpoint of 
this extension study was to evaluate the long-term efficacy of 
secukinumab with respect to the proportion of patients achieving 
20% or greater, 50% or greater, or 70% or greater improvement in 
the American College of Rheumatology (ACR) criteria for improve-
ment (ACR20, ACR50, and ACR70, respectively) over time, up 
to 5 years in patients with active PsA who completed the core 
study. ACR20/50/70 responses are reported for those patients 
who were originally randomized to secukinumab 150 mg during 
the core study to show the full 5-year efficacy and separately 
for those who entered the extension study in the secukinumab 
150  mg group (including patients both originally randomized 
to secukinumab 150 mg and those switched from placebo to 
secukinumab 150 mg at week 16 or 24).
Other assessments that continued for up to 5 years 
included resolution of dactylitis and enthesitis, which were meas-
ured using the Leeds Dactylitis and Leeds Enthesitis Indices, 
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respectively; change from baseline in Health Assessment 
Questionnaire-Disability Index (HAQ-DI); Short Form 36-item (SF-
36) health survey physical component summary (PCS); improve-
ment (75% or greater and 90%) in Psoriasis Area and Severity 
Index responses (PASI 75/90); change from baseline in Disease 
Activity Score-28 (DAS28; utilizing high-sensitivity C-reactive 
protein); the proportion of patients achieving low disease activity 
(LDA) and disease remission based on DAS28 scores of 3.2 or 
less and 2.6 or less, respectively, and the proportion of patients 
achieving minimal disease activity (MDA; defined as having 5 out 
of 7 of the following: 1 or fewer tender joint count, 1 or fewer 
swollen joint count, PASI ≤ 1 or Investigator’s Global Assessment  
[IGA] score ≤ 1, patient pain visual analog scale [VAS] ≤ 15, patient 
global VAS ≤ 20, HAQ-DI ≤ 0.5, tender entheseal points ≤ 1).
Long-term safety and tolerability of secukinumab were 
assessed by monitoring vital signs, clinical laboratory variables, 
and treatment-emergent adverse events (AEs) over time, up to 84 
days after the last administration of treatment.
Statistical analysis. Efficacy data are presented using all 
observed data at the given time point of analysis based on the 
Full Analysis Set (FAS), which included all subjects with at least 
one efficacy assessment during the extension. For patients who 
discontinued during a specific period, the end-of-treatment visit 
(ie, final assessment 4 weeks after last study treatment) was con-
sidered the last week of the corresponding period. PASI assess-
ments were conducted for subjects in whom at least 3% of the 
body surface area was affected by psoriatic skin involvement at 
baseline. Dactylitis/enthesitis assessments are presented among 
patients with dactylitis/enthesitis at baseline. Analysis is presented 
in a descriptive manner through week 260.
Graphical representation (line plots) of ACR20, ACR50, 
and ACR70 response over time are provided for patients ini-
tially randomized to the 150-mg dose. Sankey-style bar charts 
for the ACR and PASI responses for all patients (including 
patients who were initially randomized to placebo followed by 
secukinumab 150 mg) that escalated from 150 to 300 mg and 
had efficacy assessments at both up to 32 and up to 56 weeks 
after escalation were also drawn from the observed data. The 
Table 1. Demographics and baseline characteristics of patients 
who entered the extension phase receiving secukinumab 150 mga
Characteristicb
Secukinumab  
150 mg (N = 236)
Age (years) 49.3 (11.57)
Female, n (%) 121 (51.3)
Weight (kg) 82.7 (19.70)
BMI (kg/m2) 28.5 (6.47)
Time since first diagnosis of PsA (years) 7.63 (7.927)
Disease history and baseline characteristics
Anti–TNF-naïve, n (%) 178 (75.4)
Methotrexate use at randomization, n (%) 148 (62.7)
Systemic glucocorticoid use at  
randomization, n (%)
37 (15.7)
Tender joint count (78 joints) 23.3 (16.90)
Swollen joint count (76 joints) 13.1 (10.25)
HAQ-DI 1.142 (0.667)
DAS28-CRP 4.72 (1.079)
Psoriasis (≥3% body surface area), n (%) 130 (55.1)
Presence of dactylitis, n (%) 123 (52.1)
Presence of enthesitis, n (%) 141 (59.7)
Abbreviation: BMI, body mass index; DAS28-CRP, Disease Activity 
Score-28-C-reactive protein; HAQ-DI, Health Assessment Question-
naire-Disability Index; PsA, psoriatic arthritis; TNF, tumor necrosis 
factor.
aBaseline characteristics were recorded at baseline of the core study. 
bResults are mean (standard deviation) unless otherwise stated. 
Figure 1. Patient disposition during the extension phase.
Week 104
236 patients in the FAS entered 
the extension phase in the 
secukinumab 150 mg groupa
21 Discontinued
• Adverse event (n=5)
• Lack of efficacy (n=1)
• Lost to follow-up (n=2)
• Pregnancy (n=1)
• Subject/guardian decision (n=11)
• Death (n=1)
14 Discontinued
• Adverse event (n=4)
• Lack of efficacy (n=3)
• Lost to follow-up (n=1)
• Pregnancy (n=1)
• Subject/guardian decision (n=5)
8 Discontinued
• Lost to follow-up (n=1)
• Physician decision (n=2)
• Technical problems (n=2)
• Subject/guardian decision (n=3)
193 patients completed
5 years of treatment
5th year of 
treatment
4th year of 
treatment
3rd year of 
treatment
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Sankey-style overlay presents ACR and PASI responses using 
mutually exclusive definitions.
The safety set included all patients who took at least one 
dose of study treatment during the treatment period in the core 
or extension study. Evaluation of AEs is based on the secuki-
numab dose taken prior to the AE and presented as expo-
sure-adjusted incidence rates (EAIRs) per 100 patient-years over 
the entire treatment period for each treatment dose and overall. 
If a patient experienced an AE after dose escalation, the patient 
was counted at the escalated dose.
RESULTS
Baseline characteristics and subject disposition. 
Baseline demographics and disease characteristics for patients 
in the secukinumab 150-mg FAS group (including patients who 
switched from placebo to secukinumab 150 mg) are shown in 
Table 1. The patient retention rates in this 5-year study were high, 
with over 80% of patients who entered the extension study com-
pleting the full treatment period (Figure 1). Of the 236 FAS patients 
in the secukinumab 150-mg group, 193 (81.8%) completed 5 years 
of treatment, with 86 of 236 (36.4%) patients having escalated to 
300 mg; of these 193 patients, 149 (77.2%) were TNF-naïve.
Disease activity assessed by ACR responses. The 
ACR20/50/70 responses reported during the core study for the 
group of patients who were originally randomized to secuki-
numab 150 mg were sustained through 5 years (Figure 2) with 
responses of 67.9%/52.7%/37.4% at 5 years. ACR responses 
were similar in the secukinumab 150 mg group that included 
patients who switched from placebo at week 16 or 24 (Table 2).
ACR response rates achieved in the core study were sustained 
through 5 years in both anti–TNF-naïve and anti–TNF-IR groups, 
with generally higher responses observed in anti–TNF-naïve patients 
across the entire treatment period (Figure 2). ACR responses were 
generally similar regardless of whether patients were receiving con-
comitant methotrexate or not (Supplementary Table 1).
Disease remission/LDA based on DAS28-CRP. The 
proportions of patients who achieved disease remission and 
LDA states according to DAS28-CRP in the secukinumab 
150-mg group (including those who switched from placebo 
Figure 2. ACR20/50/70 responses up to 5 years in the secukinumab 150-mg group. To show the full 5-year efficacy, results are shown for 
the group of patients who were originally randomized to secukinumab 150 mg during the core study and entered the extension study in the 
secukinumab 150 mg group; patients who switched from placebo to secukinumab 150 mg at weeks 16 and 24 are not included in these 
figures. ACR 20/50/70, American College of Rheumatology criteria for 20%/50%/70% improvement in disease activity.
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to secukinumab 150 mg) at 2 years during the core study 
improved yearly through 5 years (Table 2). At 5 years, 60.8% and 
75.3% of patients in the secukinumab 150-mg group achieved 
DAS28-CRP disease remission and LDA states, respectively.
Resolution of enthesitis and dactylitis. Resolution of 
dactylitis and enthesitis achieved with secukinumab 150 mg up to 
2 years were sustained through 5 years, with 93.9% and 78.8% of 
patients achieving complete resolution of dactylitis and enthesitis, 
respectively, at 5 years (Table 2).
Efficacy across other endpoints. Efficacy responses 
reported during the core study with secukinumab 150 mg 
were also sustained throughout the extension study for the 
following parameters: PASI90 and PASI75, HAQ-DI response, 
SF-36 PCS, and MDA (Table  2). At 5 years, high PASI75 
(80.6%) and PASI90 (67.0%) responses were observed, and 
MDA response was 39.5% (Table 2).
Efficacy following dose escalation. The majority of 
patients showed improvements in their ACR and PASI responses 
after dose escalation from 150 to 300 mg (Figure 3). Lower pro-
portions of patients were ACR nonresponders (fewer than 20) 
after escalation from 150 to 300 mg at 12 to 32 weeks (40 of 126 
patients, 31.7%) and 36 to 56 weeks (35 of 126 patients, 27.8%) 
compared with before escalation (54 of 126, 42.9%). Responses 
for higher hurdle ACR endpoints (ACR50 and ACR70) were 
achieved by greater proportions of patients at 12 to 32 weeks (55 
of 126 patients, 43.7%) and 36 to 56 weeks (64 of 126 patients, 
50.8%) after escalation from 150 to 300 mg compared with before 
dose escalation (40 of 126 patients, 31.7%) (Figure 3). At 5 years 
in the secukinumab group (including patients who switched from 
placebo to secukinumab 150 mg), ACR20/50/70 responses were 
71.8%/51.8%/39.1%, respectively, in those receiving 150 mg (n 
= 110) and 69.9%/51.8%/32.5%, respectively, in those who had 
escalated to 300 mg (n = 83).
Similarly, lower proportions of patients were PASI nonre-
sponders (less than 50) after escalation from 150 to 300 mg at 
12 to 32 weeks (9 of 80 patients, 11.3%) and 36 to 56 weeks (7 
of 80 patients, 8.8%) compared with those before escalation (16 
of 80, 20.0%). Responses for the high hurdle endpoint PASI90 
were achieved by greater proportions of patients at 12 to 32 
weeks (38 of 80 patients, 47.5%) and 36 to 56 weeks (47 of 
80 patients, 58.8%) after dose escalation compared with before 
escalation (27 of 80 patients, 33.8%). At 5 years in the secuki-
numab group (including patients who switched from placebo to 
secukinumab 150 mg), PASI75/PASI90 responses were 86.3% 
and 78.4%, respectively, in those receiving 150 mg (n = 51) and 
75.0% and 55.8%, respectively, in those who had escalated to 
300 mg (n = 52).
Table 2. Summary of efficacy results during the extension phasea
Efficacy Endpoints 
Secukinumab 150 mg (N = 236)
Year 2b  Year 3b  Year 4b  Year 5c
ACR20 158/213 (74.2) 168/229 (73.4) 142/211 (67.3) 137/193 (71.0)
ACR50 99/213 (46.5) 122/229 (53.3) 103/211 (48.8) 100/193 (51.8)
ACR70 58/213 (27.2) 71/229 (31.0) 64/211 (30.3) 70/193 (36.3)
PASI 75d 93/117 (79.5) 95/127 (74.8) 86/120 (71.7) 83/103 (80.6)
PASI 90d 73/117 (62.4) 72/127 (56.7) 68/120 (56.7) 69/103 (67.0)
Resolution of dactylitise 92/107 (86.0) 106/121 (87.6) 102/113 (90.3) 93/99 (93.9)
Resolution of enthesitisf 96/130 (73.8) 106/137 (77.4) 94/123 (76.4) 89/113 (78.8)
DAS28-CRP remission 101/213 (47.4) 116/229 (50.7) 111/212 (52.4) 118/194 (60.8)
DAS28-CRP LDA 128/213 (60.1) 149/229 (65.1) 143/212 (67.5) 147/194 (75.3)
Minimal Disease Activity 76/215 (35.3) 79/232 (34.1) 82/216 (38.0) 77/195 (39.5)
HAQ-DI BL (SD) 1.12 (0.661) 
[n = 213]
1.14 (0.671) 
[n = 229]
1.13 (0.662) 
[n = 210]
1.09 (0.650) 
[n = 193]
mean change from 
BL (SD)
−0.40 (0.587) 
[n = 213]
−0.39 (0.632) 
[n = 229]
−0.37 (0.644) 
[n = 210]
−0.39 (0.626) 
[n = 193]
SF-36 PCS BL (SD) 38.39 (7.929) 
[n = 207]
38.15 (7.80) 
[n = 230]
38.19 (7.734) 
[n = 213]
38.39 (7.811) 
[n = 192]
mean change from 
BL (SD)
5.72 (7.893) 
[n = 207]
5.43 (8.417) 
[n = 230]
5.52 (8.350) 
[n = 213]
6.04 (8.341) 
[n = 192]
Abbreviation: ACR, American College of Rheumatology; BL, baseline; DAS28-CRP, Disease Activity Score 28-joint count 
C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; LDA, low disease activity; M, The total number 
of patients evaluated in the treatment group; PASI90, 90% improvement in Psoriasis Area and Severity Index; SF-36 PCS, 
Short Form-36 Physical Component Summary.
aResults are n/M (%) unless otherwise stated. Results are shown for patients who entered the extension phase in the secuki-
numab 150-mg group, including patients who switched from placebo to secukinumab 150 mg at weeks 16/24. 
bAll patients received secukinumab 150 mg. 
cIncludes 83 patients who had dose escalation from 150 to 300 mg based on physician’s judgement from week 156 onward. 
dPatients with psoriasis affecting ≥3% body surface area at baseline (n = 89 [150 mg] and 82 [75 mg]). 
ePatients (n = 83 [150 mg] and 77 [75 mg]) with dactylitis at baseline, as measured using the Leeds Dactylitis Index. 
fPatients (n = 99 [150 mg] and 91 [75 mg]) with enthesitis at baseline, as measured using the Leeds Enthesitis Index. 
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Safety. Safety is reported as EAIR/100 patient-years for 
all patients (N = 587) who were administered at least one dose 
of study treatment during the core or the extension study. 
The type, incidence, and severity of AEs over the 260-week 
treatment period were consistent with those reported at year 
1 and year 2. The EAIR of AEs and serious AEs observed with 
secukinumab are shown in Table 3. The majority of AEs with 
the highest EAIRs were infections usually involving the upper 
respiratory tract (EAIR = 8.0 for any dose of secukinumab), 
whereas the most common AE was nasopharyngitis (EAIR = 
8.6 for any dose of secukinumab).
Six deaths were reported during this 5-year study. Two 
of these deaths occurred during the core study: one died of 
stroke/cerebrovascular accident (a patient receiving secuki-
numab 75 mg), and one died of myocardial infarction (a patient 
receiving secukinumab 150 mg); but the other four deaths 
occurred during the extension phase: one patient receiving 
secukinumab 75 mg died from squamous cell carcinoma of 
the pharynx, the other three patients, in the secukinumab 150-
mg group, died from acute myocardial infarction, cardiac fail-
ure, and septic shock, respectively.
The EAIR for Crohn’s disease was 0.2 for the entire 5-year 
period. Confirmed cases of Crohn’s disease were reported during 
the core study for one patient in the secukinumab 75-mg group 
(23-year-old male with no history of IBD; the event was graded 
as severe and the patient discontinued; the investigator did not 
suspect a relationship to study treatment) and one patient in the 
placebo group (exacerbation). One additional confirmed case 
of Crohn’s disease was reported for one patient in the secuki-
numab 75-mg group during the extension study (68-year-old 
male with no history of IBD; the event was graded as moderate 
in severity and the patient remained in the study; the investigator 
did not suspect a relationship to study treatment).
The EAIR for Candida infections was 0.9 for patients 
treated with any dose of secukinumab during the entire treat-
ment period. The infections were located in the skin and 
mucus membranes, none were systemic or invasive, and all 
except one were nonserious, mild, or moderate in severity, 
responded to standard therapy, and did not lead to study 
treatment discontinuation. The EAIR for malignancies was 0.8 
for patientss treated with any dose of secukinumab during the 
entire treatment period.
Overall, the incidence of treatment-emergent antidrug anti-
bodies (ADAs) was low (detected in eight patients) throughout the 
Figure 3. American College of Rheumatology (ACR) and 
Psoriasis Area and Severity Index (PASI) responses up to 56 weeks 
after dose escalation from 150 to 300  mg. Before escalation is 
defined as the last assessment done on or before patient took the 
escalated dose. Patients who entered the extension phase in the 
secukinumab 150-mg group (including patients who switched from 
placebo to secukinumab 150 mg at weeks 16 and 24) and who had 
both pre- and all postdose escalation assessments data available 
are included in the analysis for ACR (n = 126) and PASI (n = 80) 
responses.
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Table 3. Safety summary across the entire 260-week treatment 
perioda
Category
Any Secukinumab 
Dose (N = 587)
Exposure to treatment – d, mean (SD) 1443.6 (616.7)
Death, n (%) 6 (1.0)
Discontinued due to AEs, n (%) 49 (8.3)
Any AE 126.7
Serious AEs 7.5
Most Common AEs
Nasopharyngitis 8.6
Upper respiratory tract infection 8.0
AEs of special interest
Serious infections 1.8
Candida infections 0.9
Crohn's disease 0.2
MACE 0.5
Malignancies 0.8
Abbreviation: AE, adverse event; EAIR, exposure-adjusted incidence 
rate; MACE, major adverse cardiac event.
aData are EAIR, unless otherwise stated. 
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5-year period; three patients were positive at baseline and con-
tinued to show ADAs, and two patients showed neutralizing anti-
bodies at week 24. A clear relationship between ADA formation 
and deviating pharmacokinetics or immunogenicity-related AEs 
was not observed.
DISCUSSION
Secukinumab demonstrated sustained improvements in 
the signs and symptoms, function, and health-related qual-
ity of life in patients with active PsA. The patient retention 
rates in this study were high, with over 80% of patients who 
entered the extension study completing the full 5-year treat-
ment period. These are the first 5-year findings reported for 
secukinumab in PsA, and the data add to the growing body 
of evidence supporting the use of IL-17 inhibitors for the treat-
ment of PsA as recognized in the guidelines from the EULAR 
(8), GRAPPA (11), and recently the ACR/National Psoriasis 
Foundation (NPF) (19).
This robust study also provides data on the benefits of dose 
escalation in patients whose symptoms are inadequately con-
trolled on 150 mg. Improvement in ACR and PASI responses was 
achieved in patients who escalated from secukinumab 150 to 300 
mg, indicating a benefit of dose escalation in patients who require 
additional control of symptoms. In agreement with previous studies 
(3,8,9,11,13–16), secukinumab treatment in FUTURE 1 was shown 
to be efficacious in both anti–TNF-naïve and anti–TNF-IR patients, 
with clinical responses generally higher in anti–TNF-naïve patients 
than in anti–TNF-IR patients. These results support the effectiveness 
of long-term treatment with secukinumab for biologic-naïve patients 
as well as for patients who have previously failed anti-TNF therapy.
The safety profile of secukinumab was consistent with 
that previously reported for PsA (3,9,12–17) and psoriasis 
(6). No new or unexpected safety signals were observed in 
patients with PsA over a treatment period of up to 5 years. 
The rates of Candida infections, major adverse cardiac events, 
and malignancies reported were low throughout the 5-year 
treatment period and consistent with results of an analysis of 
long-term safety of secukinumab in patients with psoriasis, 
PsA, and ankylosing spondylitis (20). The low rate of Crohn’s 
disease reported in the study is in line with findings of a recent 
retrospective analysis of 21 clinical trials of psoriasis, PsA, 
and ankylosing spondylitis, which found that IBD events were 
uncommon with secukinumab treatment (21). It should be 
noted that patients with active ongoing inflammatory disease 
were excluded from this study, so patients with a history of IBD 
were likely not enrolled.
Limitations of this study included a lack of a long-term com-
parator due to the fact that long-term treatment with placebo is 
considered unethical; the placebo-controlled period of the core 
trial was, therefore, only up to week 16. There was no active 
comparator included, and results could be potentially biased 
as patients remaining in the study are those patients benefiting 
from secukinumab. Although efficacy responses in the current 
study were sustained irrespective of previous anti-TNF exposure, 
patients eligible for inclusion in this study could have been treated 
with no more than three anti-TNF agents; this may be viewed as 
a limitation of the study. The inclusion of patients in this exten-
sion study based on the investigator’s judgement of their overall 
response to therapy likely resulted in a population of preselected 
responders.
Results from this long-term extension study confirm the 
benefit of IL-17 inhibition with secukinumab for sustained 
improvements in the signs and symptoms of major clinical 
domains of PsA. With no new safety concerns over a treat-
ment period of up to 5 years, results from the 5-year phase III 
FUTURE 1 study support the long-term efficacy, safety, and 
tolerability of secukinumab in the treatment of patients with 
PsA.
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